Purpose <p>The main purpose of the research work was to formulate cocrystals of Raloxifene Hydrochloride(RXL-HCl) in order to increase its solubility and oral bioavailability. The effect of addition of bioenhancer on the oral bioavailability was also examined.</p> Methods <p>Co-crystals of RXL HCl with tartaric acid as a coformer were successfully formulated with salt to coformer stoichiometric ratio of 1:1 by using solvent evaporation method. Characterization was done by FTIR analysis, SEM, DSC, pXRD, solubility, in- vitro dissolution, and in-vivo pharmacokinetic study.</p> Results <p>Optical microscopy and SEM analysis revealed the formation of plate-shaped crystals. The stretching and bending vibration patterns were different in the FTIR spectra of the developed formulation in comparison to the RXL HCl indicating the formation of the co-crystals. DSC analysis showed a melting endotherm at 235ºC which is less than that of RXL HCl indicating the formation of co-crystals. The pXRD pattern of co-crystals was different compared to that of the RXL HCl. The solubility of co-crystals in aqueous media was found to be 14.1&#xa0;mg/mL which is almost 80 folds higher compared to RXL HCl. The <i>in-vitro</i> dissolution study of co-crystals showed 82.9%, 57%, and 65% drug dissolution after 120&#xa0;min in water, acidic media, and alkaline media respectively, which is significantly greater compared to the RXL HCl. The <i>in-vivo</i> pharmacokinetic study showed almost 6 folds higher bioavailability compared to the marketed product.</p> Conclusion <p>Administration of cocrystals of Raloxifene Hydrochloride with Naringin as a bioenhancer led to a significant enhancement in oral bioavailability.</p>